Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.
We conducted a pooled analysis of rolapitant-containing regimens versus control in the prophylaxis of chemotherapy-induced nausea and vomiting. Eligible studies included randomized studies evaluating rolapitant-containing regimens in the settings of highly emetogenic and moderately emetogenic chemotherapy. The pooled relative risk for complete response in the overall phase was 1.23 (95% CI: 1.18-1.33; p < 0.00001), the pooled relative risk for no significant nausea in the overall phase was 1.17 (95% CI: 1.04-1.32; p = 0.008) and the pooled RR for no emesis in the overall phase was 1.24 (95% CI: 1.18-1.31; p < 0.00001). Rolapitant-based regimens are associated with higher rates of complete response, no significant nausea and no emesis with highly/moderately emetogenic chemotherapy compared with control regimens.